bioRxiv Science⌕ Search

Biology subjects

Junker, N.

Publications and source records attributed to Junker, N..

2 recordsLinked to original sources

Enzyme-functionalized microparticles to open the vitreoretinal interface

The transport of therapeutics and gene carriers to their site of action is often hindered by biological barriers, such as cell layers and basement membranes. Among these, the inner limiting membrane (ILM) represents a major barrier within the eye, separating the vitreous body from the retina. The ILM must be crossed, if for instance gene carriers are to reach retinal target cells following intravitreal administration. However, the ILM is a densely cross-linked basement membrane barrier, allowing only the smallest nanoparticles to pass. Here, we demonstrate that active micro-colloids decorated with enzymes can locally open the ILM and thereby facilitate the diffusion of passive carriers into retinal tissue. We utilize an ex vivo porcine eye model to determine the membrane permeability threshold using fluorescent nanoprobes. We further show that collagenase-decorated silica microparticles can facilitate the transport of nanoparticles, while exhibiting excellent biocompatibility with no adverse morphological or functional retinal effects over a six-week in vivo evaluation in a porcine model. Overall, our findings introduce a biocompatible and minimally invasive strategy to facilitate the targeted nanoparticle transport across biological barriers, which we demonstrate for retinal delivery enabled by active colloids.

bioengineering↗

Propranolol reduces sarcoma growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment

The nonselective beta blocker, propranolol, which for decades has been prescribed for treatment of cardiovascular conditions, has recently been used successfully to treat metastatic angiosarcoma. These results have led to an orphan drug designation by the European Medicines Agency for the treatment of soft tissue sarcomas. The anti-tumor effects of propranolol are suggested to involve the reduction of cancer cell proliferation as well as angiogenesis. Here, we have investigated the anti-angiogenic properties of propranolol in the context of stimulating an anti-tumor immune response. We show that oral administration of propranolol delays tumor progression of MCA205 fibrosarcoma tumors and increases the survival rate of tumor bearing mice. Propranolol works by reducing tumor angiogenesis and facilitating an anti-tumoral microenvironment with increased T cell infiltration and reduced infiltration of myeloid-derived suppressor cells (MDSCs). Using T cell deficient mice, we demonstrate that the full anti-tumor effect of propranolol requires the presence of T cells. Flow cytometry-based analysis and RNA sequencing of FACS-sorted cells show that propranolol-treatment leads to an upregulation of PD-L1 on tumor-associated macrophages (TAMs) and changes in their chemokine expression profile. Lastly, we observe that the co-administration of propranolol significantly enhances the efficacy of anti-CTLA4 therapy. Our results identify propranolol as an immune modulating agent, which can improve immune checkpoint inhibitor therapies in soft tissue sarcoma patients and potentially in other cancers.

cancer biology↗